EyePoint Inc. Common Stock (EYPT)
Stock · NASDAQ · Industrials
$2.99as of 10/16/2026
Price chart
Active signals
EYPT Signal Track Record
How signals performed across all stocks →What EYPT's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 41 | +4.2% | 56% | September 16, 2026 |
| Bollinger Band Breakdown | 23 | -5.9% | 43% | August 17, 2026 |
| Bollinger Band Breakout | 22 | -0.1% | 50% | August 14, 2026 |
| 200-Day Moving Average TouchActive now | 6 | -10.7% | 33% | June 29, 2026 |
| Any 20-session window (baseline) | -3.7% | 45% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About EYPT
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining…
- Sector
- Industrials
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Employees
- 214
- Website
- eyepoint.bio/
Fundamentals
- 1-day range
- $3.01$3.18
- Market cap
- $1.08B
- P/E (trailing)
- —
- P/E (forward)
- -1.13
- EPS (trailing)
- $-3.74
- Dividend yield
- —
- Beta
- 1.68
- Avg. volume
- 4.03M
- Dividend pay date
- December 9, 2020
How EyePoint Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 5, 2026 · via SEC EDGAR / Finnhub
Forecasts
11 analyst ratings
EyePoint Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- EYPTEyePoint Inc. Common Stock$2.99▼ 4.78%Market cap $1.08BP/E —$2.93$19.11
- CTKBCytek Biosciences Inc. Common Stock$5.25▼ 2.96%Market cap $537.23MP/E —$3.31$6.21
- PACBPacific Biosciences of California Inc. Common Stock$1.73▼ 11.73%Market cap $361.85MP/E —$1.07$3.44
- LABStandard BioTools Inc. Common Stock$0.63▼ 4.55%Market cap $313.21MP/E 2.92$0.6251$1.72
- QTRXQuanterix Corporation Common Stock$2.87▼ 6.51%Market cap $180.42MP/E —$2.15$8.77
- SEERSeer Inc. Class A Common Stock$2.03▼ 0.49%Market cap $120.41MP/E —$1.55$2.41
- NAUTNautilus Biotechnology Inc. Common Stock$2.06▼ 4.63%Market cap $112.76MP/E —$0.8399$4.31
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| EYPT EyePoint Inc. Common Stock | $1.08B | — | $2.99 | ▼ 4.78% | $2.93$19.11 |
| CTKB Cytek Biosciences Inc. Common Stock | $537.23M | — | $5.25 | ▼ 2.96% | $3.31$6.21 |
| PACB Pacific Biosciences of California Inc. Common Stock | $361.85M | — | $1.73 | ▼ 11.73% | $1.07$3.44 |
| LAB Standard BioTools Inc. Common Stock | $313.21M | 2.92 | $0.63 | ▼ 4.55% | $0.6251$1.72 |
| QTRX Quanterix Corporation Common Stock | $180.42M | — | $2.87 | ▼ 6.51% | $2.15$8.77 |
| SEER Seer Inc. Class A Common Stock | $120.41M | — | $2.03 | ▼ 0.49% | $1.55$2.41 |
| NAUT Nautilus Biotechnology Inc. Common Stock | $112.76M | — | $2.06 | ▼ 4.63% | $0.8399$4.31 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- OCUL Stock Suffers Sharpest Drop Since February As KOD And FDMT Post Updates On Their Wet AMD DrugsYahoo · 9/28/2026
- Xenon Pharmaceuticals, Steel Dynamics, Nucor And Other Big Stocks Moving Lower In Friday’s Pre-Market SessionBenzinga · 9/18/2026
- EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Yahoo · 9/16/2026
- EyePoint, Inc. (EYPT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeekingAlpha · 9/15/2026
Insider Activity
Insider Actions →- George Elston · August 20, 2026 · Gift65.0K
- George Elston · August 20, 2026 · J5.0K
- Karen L. Zaderej · August 18, 2026 · Buy10.6K @ $4.93
- Jay S. Duker · July 10, 2026 · Option Exercise16.7K
- Jay S. Duker · July 10, 2026 · Tax Withholding8.1K @ $14.72
- Ramiro Ribeiro · June 30, 2026 · Option Exercise2.4K @ $8.26
- Ramiro Ribeiro · June 30, 2026 · Option Exercise2.4K @ $8.26
- Ramiro Ribeiro · June 30, 2026 · Sale2.4K @ $15.02
- Ramiro Ribeiro · June 30, 2026 · Sale2.4K @ $15
- George Elston · May 25, 2026 · Option Exercise7.5K
- George Elston · May 25, 2026 · Tax Withholding3.6K @ $12.93
- Ramiro Ribeiro · April 17, 2026 · Option Exercise2.4K @ $8.26
- Ramiro Ribeiro · April 17, 2026 · Sale2.4K @ $15
Institutional Ownership
March 31, 2026
- Total shares held
- 88.92M
- Total value held
- $1.14B
- Institutional holders
- 183
- Unknown8.30M
- Unknown8.27M
- Unknown7.18M
- Unknown5.67M
- Unknown5.05M
- Unknown3.60M
- Unknown3.56M
- Unknown3.30M
- Unknown3.14M
- Unknown2.83M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Yahoo article highlights EYPT as a potential portfolio addition
A recent Yahoo article discussed EyePoint Inc. (EYPT) and listed reasons why the stock could be considered for a portfolio. The piece referenced the company's analyst consensus target of $25.91 and its 52‑week range of $2.93 to $19.11. The article’s positive tone adds to current market conversation around the stock.
Yahoo article highlights EYPT as a potential portfolio addition. A recent Yahoo article discussed EyePoint Inc. (EYPT) and listed reasons why the stock could be considered for a portfolio. The piece referenced the company's analyst consensus target of $25.91 and its 52‑week range of $2.93 to $19.11. The article’s positive tone adds to current market conversation around the stock.